Prolactinomas
Mostrando 1-12 de 53 artigos, teses e dissertações.
-
1. O que é hiperprolactinemia? Como deve ser a abordagem na Atenção Primária?
Fisiológicas
GravidezAmamentação
Farmacológicas
Neurolépticos (fenotiazinas, butirofenonas, risperidona, sulpirida)Antidepressivos tricíclicos (amitriptilina, clomipramina)Inibidores da monoaminoxidaseAnti-hipertensivos (verapamil, reserpina, metildopa)
Fenitoína
Medicamentos de ação intestinal (domperidona, m
Núcleo de Telessaúde HC UFMG. Publicado em: 12/06/2023
-
2. Sexual stigma, attachment difficulties, and emotional dysregulation among patients with severe mental illness
Objective: To evaluate body dissatisfaction and distorted body self-image in women with prolactinoma. Methods: Body dissatisfaction and distorted body self-image were evaluated in 80 women with prolactinoma. All patients were in menacme, 34% had normal body mass index (BMI), and 66% were overweight. Most patients (56.2%) had normal prolactin (PRL) levels a
Braz. J. Psychiatry. Publicado em: 2020-02
-
3. The importance of assessing personality traits and disorders in clinical trials of major depressive disorder
Objective: To evaluate body dissatisfaction and distorted body self-image in women with prolactinoma. Methods: Body dissatisfaction and distorted body self-image were evaluated in 80 women with prolactinoma. All patients were in menacme, 34% had normal body mass index (BMI), and 66% were overweight. Most patients (56.2%) had normal prolactin (PRL) levels a
Braz. J. Psychiatry. Publicado em: 2020-02
-
4. Comment on “Transcranial magnetic stimulation of the medial prefrontal cortex for psychiatric disorders: a systematic review”
Objective: To evaluate body dissatisfaction and distorted body self-image in women with prolactinoma. Methods: Body dissatisfaction and distorted body self-image were evaluated in 80 women with prolactinoma. All patients were in menacme, 34% had normal body mass index (BMI), and 66% were overweight. Most patients (56.2%) had normal prolactin (PRL) levels a
Braz. J. Psychiatry. Publicado em: 2020-02
-
5. Body self-image disturbances in women with prolactinoma
Objective: To evaluate body dissatisfaction and distorted body self-image in women with prolactinoma. Methods: Body dissatisfaction and distorted body self-image were evaluated in 80 women with prolactinoma. All patients were in menacme, 34% had normal body mass index (BMI), and 66% were overweight. Most patients (56.2%) had normal prolactin (PRL) levels a
Braz. J. Psychiatry. Publicado em: 2020-02
-
6. Body self-image disturbances in women with prolactinoma
Objective: To evaluate body dissatisfaction and distorted body self-image in women with prolactinoma. Methods: Body dissatisfaction and distorted body self-image were evaluated in 80 women with prolactinoma. All patients were in menacme, 34% had normal body mass index (BMI), and 66% were overweight. Most patients (56.2%) had normal prolactin (PRL) levels a
Braz. J. Psychiatry. Publicado em: 15/07/2019
-
7. Controversial issues in the management of hyperprolactinemia and prolactinomas – An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism
ABSTRACT Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and they represent an important cause of hypogonadism and infertility in both sexes. The magnitude of prolactin (PRL) elevation can be useful in determining the etiology of hyperprolactinemia. Indeed, PRL levels > 250 ng/mL are highly suggestive of the presence of a p
Arch. Endocrinol. Metab.. Publicado em: 2018-03
-
8. Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina
ABSTRACT Objectives The main purpose of this study was to estimate the incidence rate and prevalence of clinically relevant pituitary adenomas (PAs) within the Hospital Italiano Medical Care Program (HIMCP), a well-defined population of 150,000 members living in the urban and suburban area of the city of Buenos Aires. We defined clinically relevant PAs as
Arch. Endocrinol. Metab.. Publicado em: 25/08/2016
-
9. A review on the diagnosis and treatment of patients with clinically nonfunctioning pituitary adenoma by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism
ABSTRACT Clinically nonfunctioning pituitary adenomas (NFPA) are the most common pituitary tumors after prolactinomas. The absence of clinical symptoms of hormonal hypersecretion can contribute to the late diagnosis of the disease. Thus, the majority of patients seek medical attention for signs and symptoms resulting from mass effect, such as neuro-ophthalmo
Arch. Endocrinol. Metab.. Publicado em: 2016-08
-
10. Prolactinomas podem ter apresentações incomuns resultantes de maciça extensão tumoral extrasselar
RESUMO O objetivo desta série de casos é relatar oito pacientes com prolactinomas gigantes enfatizando as formas de apresentação e uma complicação do tratamento. O estudo incluiu seis homens e duas mulheres. A mediana de idade foi 29 anos (18–54); e dos níveis de prolactina foi 4.562 ng/ml (1.543–18.690); três pacientes (37,5%) apresentaram pan-h
Arq. Neuro-Psiquiatr.. Publicado em: 2016-07
-
11. Mean platelet volume in patients with prolactinoma
ABSTRACT Objective Prolactin is a multifunctional pituitary hormone. The effect of prolactin on platelet activation is not well understood. Prolactinomas are the most common type of pituitary adenomas, and they are medically responsive to dopamine agonists. Mean platelet volume (MPV) is a marker of platelet function and activation. The aim of this study wa
Arch. Endocrinol. Metab.. Publicado em: 16/02/2016
-
12. Prolactinomas: evolution after menopause
ABSTRACT Objetive The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. Retrospective study, 29 patients with prolactinomas, 22 microadenomas and 7 macroadenomas, diagn
Arch. Endocrinol. Metab.. Publicado em: 2016-02